KRMD

KORU Medical Systems, Inc. (KRMD) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions, primarily for the delivery of immunoglobulin to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company operates as a single segment with revenue streams from domestic core, international core, and pharma services/clinical trials.

Key Financial Metrics

Note: The company has no outstanding borrowings on its $10 million credit facility (revolver and term loan) as of June 30, 2026.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 18.2% year-over-year (Q2) and 20.1% year-over-year (YTD). This was driven by a 12.4% increase in domestic core revenue and a 59.1% surge in international core revenue, partially offset by a 35% decline in pharma services and clinical trials revenue in Q2.
• Profitability: The company reported a net income of $0.25 million for Q2 2026, a significant turnaround from a net loss of $0.21 million in Q2 2025. Gross margin improved to 65.1% in Q2 from 63.5% in the prior year, attributed to lower manufacturing costs and higher average selling prices.
• Operating Expenses: Total operating expenses rose 6.3% in Q2, primarily due to a $0.6 million increase in selling, general, and administrative (SG&A) expenses driven by new hires and legal fees. R&D expenses decreased 10.5% in Q2.
• Unusual Items: The Q2 results included a $0.41 million loss on the disposal of fixed assets. Additionally, the company recorded a $0.96 million acquisition of intangible assets (technology), partially settled with stock.

Guidance, Outlook, and Risks

• Liquidity: Management expects cash on hand ($8.3 million), operating cash flows, and the available credit facility to be sufficient for operations through the next 12 months. Future capital needs may require additional debt or equity financing.
• Debt Facility Update: In March 2026, the company amended its credit agreement to extend the revolver maturity to March 2028 and the term loan maturity to December 2029. The interest rate floor was lowered to 5.50%, and the adjusted quick ratio covenant was replaced with a liquidity covenant.
• Risks: Key risks include dependence on the subcutaneous immunoglobulin (SCIg) market, regulatory compliance (FDA), reimbursement changes, and potential impacts from tariffs on imported materials. The company noted that while some tariffs may be refundable, no benefit has been recorded.
• Management Changes: CEO Linda Tharby retired effective June 30, 2026, transitioning to a non-executive advisory role. Adam Kalbermatten is listed as the Chief Executive Officer signing the report.

Investor Verification Checklist

• Revenue Sustainability: Verify the drivers behind the 59.1% international growth (distributor purchases for pre-filled syringe conversions) to ensure it is not a one-time stockpiling event.
• Pharma Services Volatility: Assess the impact of the 35% Q2 decline in pharma services revenue on future cash flow stability.
• Asset Disposal: Review the details of the $0.41 million loss on fixed asset disposal to understand if it indicates broader asset impairment or strategic divestiture.
• Stock-Based Compensation: Monitor the $1.14 million in stock-based compensation expense (YTD) and the forfeiture of 580,000 shares related to the former CEO's departure.
• Covenant Compliance: Confirm ongoing compliance with the new "remaining months liquidity" covenant on the credit facility.